Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts

To explore mechanisms by which SGLT2 inhibitors protect diabetic hearts from heart failure, we examined the effect of empagliflozin (Empa) on the ultrastructure of cardiomyocytes in the noninfarcted region of the diabetic heart after myocardial infarction (MI). OLETF, a rat model of type 2 diabetes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Masashi, Kuno, Atsushi, Yano, Toshiyuki, Miki, Takayuki, Oshima, Hiroto, Sato, Tatsuya, Nakata, Kei, Kimura, Yukishige, Tanno, Masaya, Miura, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014462/
https://www.ncbi.nlm.nih.gov/pubmed/29932506
http://dx.doi.org/10.14814/phy2.13741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014462/
https://www.ncbi.nlm.nih.gov/pubmed/29932506
http://dx.doi.org/10.14814/phy2.13741

Ejemplares similares